Educational Archives

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018

cxsymposium2019-09-09T09:16:45+01:00

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
Ulf Teichgräber, Jena, Germany

Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018cxsymposium2019-09-09T09:16:45+01:00

cxsymposium2019-09-09T09:19:47+01:00

EVAS is associated with a reduction in all-cause mortality
Marc Schermerhorn, Boston, United States

EVAS is associated with a reduction in all-cause mortalitycxsymposium2019-09-09T09:19:47+01:00

cxsymposium2018-04-26T13:27:11+01:00

Podium 1st: Lutonix AV IDE interim 24 month update
Kate Steiner, Stevenage, United Kingdom

Podium 1st: Lutonix AV IDE interim 24 month updatecxsymposium2018-04-26T13:27:11+01:00